-
Melanoma: Understanding, Diagnosing, and Treating Skin Cancer(Post)
Melanoma is an aggressive type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, which gives skin its color. Although it is less common than othe
ICOS: Stimulating the Immune System for Superior Cancer Therapy(Post)Immunotherapy has transformed the landscape of cancer treatment by leveraging the body’s immune system to target and destroy cancer cells. A key player in this process is Inducible T-cell
TIM-3/Gal-9 Pathway in Antiparasitic Immunity(Post)Exploring the Role of TIM-3/Gal-9 in Antiparasitic ImmunityIntroductionThe immune system is a complex network of cells and molecules that work together to defend the body against pathogens, including
OX40 Agonists: Revitalizing the Immune Response in Cancer(Post)Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40
BTLA: A Key Player in Immune Regulation and Cancer Therapy(Post)Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressing T
Mechanisms of HIV persistence during HAART(Post)HIV Virus: Replication Cycle and Pathogenesis in absence of HAART The human immunodeficiency virus (HIV) is a formidable pathogen that has posed a significant global
B7-H4: A New Frontier in Immune Checkpoint Inhibition(Post)The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi
After Tocilizumab, IL-6 Goes Up. That Is the Drug Working.(Post)Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy(Post)What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
CTLA-4 in Breast Cancer: Insights for Immunotherapy(Post)The Role of CTLA-4 in Breast Cancer: Implications for ImmunotherapyBreast cancer (BC) remains one of the most prevalent malignancies affecting women worldwide, with significant morbidity and mortality
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
CAR-NK Cell Therapy: The Next Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a relentless battle of incremental gains. While immunotherapies like CAR-T cell therapy have offered revolutionary hope, their personalized nature, high
Immunometabolism – A therapeutic perspective(Post)What is Immunometabolism? Immunometabolism is an exponentially growing, multi-disciplinary field of research aiming at deciphering the dynamic cellular and mole
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
Adaptive immune system molecules(Page) Immune Regulation in COVID-19 (Post)Immune Regulation in COVID-19: Immunomodulatory Mechanisms against SARS-CoV-2 Infection What is COVID-19?
Data Science for Immunologists | Assay Genie(Post)By Dr. Niclas Thomas “Data science” is a recent addition to the vocabulary of analytics, and can mean many different things to different people. As far as
Diabetic Retinopathy: premature cellular senescence and microvascular dysfunction(Post)By Pietro Maria Bertelli, PhD Candidate, Queens University Belfast Introduction Eye complications are very frequent in patients with diabetes, and thi
Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
TIGIT: A New Frontier in Cancer and Autoimmune Disease Immunotherapy(Post)TIGIT (T cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy and the treatment of autoimmune diseases. As a checkpoint receptor, TIGIT